BeiGene's BRUKINSA Shows 74% 6-Year PFS in Treatment-Naïve CLL
This data provides strong evidence for BRUKINSA's long-term efficacy and durability in a significant patient population.
Long-term efficacy data (6-year PFS) for BRUKINSA in treatment-naïve CLL.
BeiGene reported landmark 6-year progression-free survival (PFS) data for BRUKINSA (zanubrutinib) in patients with treatment-naïve chronic lymphocytic leukemia (CLL). The data demonstrated a 74% PFS rate at six years, reinforcing BRUKINSA's efficacy and durability as a first-line treatment. This significant clinical outcome highlights the long-term benefit of BRUKINSA for CLL patients.
This data provides strong evidence for BRUKINSA's long-term efficacy and durability in a significant patient population. For the APAC region, where CLL is a prevalent hematological malignancy, these findings are crucial. They support the use of BRUKINSA as a preferred first-line treatment, potentially improving long-term outcomes and quality of life for numerous patients across Asia.
The long-term data for BRUKINSA in treatment-naïve CLL is highly relevant to APAC, as CLL is a significant cancer burden in the region. Demonstrating sustained efficacy over six years reinforces BRUKINSA's value proposition for healthcare providers and patients, potentially leading to wider adoption and improved patient management strategies across Asian markets.
Where this signal fits in the broader landscape.
BeiGene Announces Q4 and Full Year 2025 Financial Results
BeiGene Announces Fourth Quarter and Full Year 2025 Financial Results
BeOne Medicines Announces Q4 and FY2025 Financial Results
BeiGene's PD-1 Inhibitor Tislelizumab Approved in Japan, Challenging Global Pharma Giants
BeOne Medicines to Announce Q4 and Full Year 2025 Financial Results
https://www.beigene.com/press-releases/brukinsa-delivers-landmark-74-6-year-pfs-in-patients-with-treatment-na-ve-chronic-lymphocytic
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
Sign In